Navigation Links
Novagali Pharma Completes a EUR15 Million Fund Raising
Date:9/26/2008

EVRY, France, September 26 /PRNewswire/ -- Novagali Pharma, a French Laboratory specialized in ophthalmology announces today it has secured EUR15 million in a new financing round with the participation of the historical Company investors.

Thanks to this new contribution Novagali Pharma will continue to develop its high potential projects:

- The commercialization in France and abroad of its first

marketable product, Cationorm(R), indicated for the treatment of dry eye

symptoms,

- The development of its flagship products: Vekacia(R) (Vernal

keratoconjunctivitis), Cyclokat(R) (Dry eye), Nova21027 (Glaucoma) and

Cortiject(R) (Diabetic macular edema), and particularly for Cyclokat(R)

the phase III clinical study now in course in Europe and the one

initiated in the United States during the third quarter of 2008 as well

as the phase I finalization in patient with Cortiject(R) started in

April 2008 in the United States.

Jerome Martinez, Novagali Pharma Chief Executive Officer, says: "The total amount of this fund rising strengthens once again our investors confidence to our development strategy, our products and our technological approach. This new source of financing will help us to carry on our company development".

About Novagali Pharma : http://www.novagali.com

Novagali Pharma is an ophthalmic pharmaceutical company that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cat
'/>"/>

SOURCE Novagali Pharma SA
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Novagali Pharma Announces the Launch of Cationorm(R)
2. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
3. Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
4. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
5. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
6. New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors
7. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
8. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
9. AIT Laboratories Expands Pharma Services
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , , SINGAPORE, Dec. 2 /PRNewswire/...ns on its novel oral JAK2 inhibitor, SB1518, at Th...ng and Exposition in New Orleans. ,, Data will ...e 1 dose-escalation trial of SB1518 detailing its ...ynamic (PK/PD) profile in dose levels ranging from...
(Date:12/2/2009)... , , QUEBEC CITY, Dec. 2 /PRNewswire-Firs...X: AEZ) (the "Company"), a global biopharmaceutica...y, today announced that the U.S. Food and Drug Adm...on for the Company,s PI3K/Akt pathway inhibitor co...f relapsed/refractory multiple myeloma. Keryx Biop...
(Date:12/2/2009)... , , HOBOKEN, N.J., Dec. 2 /PRNewswire/ ...40 percent to 45 percent of Americans diagnosed wi...tinopathy. Diabetic retinopathy, damage to the re...se of blindness in people with diabetes and is one...ct, up to 80 percent of all patients who,ve had di...
(Date:12/1/2009)... , , NEW YORK, Dec. 1 /PRNewswire/ ...search report is available in its catalogue: ,,.../www.reportlinker.com/p0164494/Chromium---Global-M...mium is primarily influenced by stainless steel, w...e markets is also important for growth of chromium...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9
...r,s note: This is the fourth in a series of articl...ogy or biotechnology sectors. , , Madison, Wis....would be moving on to forming the entity. In the ...he last column that bears addressing. As a remind...cussed naming the entity. , ,These columns have b...
...e: read the first exclusive interview with David W... The new year will officially begin a new era of l...over for retiring chief executive James Barr on Ja...become president and CEO of TDS Telecommunications...ary, TDS Metrocom . , ,He will be taking over d...
...on, Wis. - Third Wave Technologies, Inc ., a man...bmitted an application to the U.S. Food and Drug A...is molecular test. , ,The test product, which Thi...rmine Cystic Fibrosis carrier status in adults, an...sting in newborns and children. Cystic Fibrosis is...
Other Biology Technology:Early Stage, Step 4: Cautionary trademark tales 2Early Stage, Step 4: Cautionary trademark tales 3
(Date:12/3/2009)...eads the world when it comes to investment in ener...g and Physical Sciences Research Council (EPSRC) C...eded: "Scientific and engineering research has alr... power solutions, but more investment is needed to...f we are to meet our carbon emission targets by 20...
(Date:12/2/2009)...ELPHIA New study results strengthen the evidence ...d of time have an increased risk for developing co...sk factors. , "This provides one more reason no...senior author Michael J. Thun, M.D., M.S., vice pr...search at the American Cancer Society. "Colorectal...
(Date:12/2/2009)...PHIA Assurance of a cancer-free status did not pr...zed tomography (CT) lung-cancer screening program ...te in a study published in Cancer Epidemiology, B... Association for Cancer Research. The December iss...findings should negate widespread concern in the l...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Cigarette smoking increases colorectal cancer risk 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Intimate abuse study finds clear links with poor health and calls for holistic primary care approach 50770 1Intimate abuse study finds clear links with poor health and calls for holistic primary care approach 50770 2Battle of the sexes benefits offspring says research 9115 1Battle of the sexes benefits offspring says research 9115 2Jackson 26amp 3B Coker to Spotlight Health Care Executive Insights 50767 1Jackson 26amp 3B Coker to Spotlight Health Care Executive Insights 50767 2Jackson 26amp 3B Coker to Spotlight Health Care Executive Insights 50767 3
...s to gaining fat, insects and mammals may have som...1, 2006, Cell Metabolism. The study finds that the...ient suite of genes involved in determining the fa...nt role in fat formation in both flies and mice. T...ct of genes on fat storage from insects to mammals...
...e you mutter about the high cost of relationship m...share your pain. In the first study to examine th...ciate professor of biology at McMaster University,... behavioural stress on microbes. His findings are ...shed by the Genetics Society of America. , "Ther...
...from Imperial College London shows that robot assi...han conventional surgery. , The team of surgeons t...improve surgical outcomes for patients undergoing ... the surgeon to line up the replacement knee parts...t 27 patients undergoing unicompartmental knee rep...
Other Biology News:Insects and mammals share common fat-building pathway, study suggests 2Sex: It's costly but worth it. Just ask a microbe 2Robot assisted surgery more accurate than conventional surgery 2
PROTEAN II XL Cell, wide format from Bio-Rad
PROTEAN II xi Cell, 20 cm, without spacers and combs from Bio-Rad
StemSep Rhesus CD4+ T Cells, 2 mL Kit from StemCell Technologies, Inc.
...100 high pressure dual piston pump and the Adept C...ility. The system is provided with PowerStream da...., The CE 4901 PowerStream software operating in ...00, offers the same data processing power as the C...
Biology Products: